OxThera – Industrifonden

OxThera AB publ kallar till extra bolagsstämma den 3 mars

OxThera currently has two products in its pipeline: Oxabact® for the treatment of Primary Hyperoxaluria, and Oxazyme®, an oxalate decarboxylase, for dietary hyperoxaluria and prevention of kidney stones OxThera has recently been granted two new US patents, three new Europeanpatents and patents in Canada, China, Hong-Kong, India and Japan. OxThera now holds proprietary rights to pharmaceutical preparations and their use for treatment of hyperoxaluria in nine patent families. The newly granted US patents have numbers US8900575 and US8940295 covering pharmaceutical compositions of oxalate OxThera. Nyhetssvepet tisdag 30 juni. 30 juni, 2020.

Oxthera

OxThera General Information Description. Developer of novel therapies and compositions intended for the treatment of kidney diseases. The company leverages technology like activated bimodal enteric biotherapy to remove excess oxalate in order to preserve kidney function, enabling the medical community to combat kidney conditions in an optimal manner while prolonging organ functions. OxThera is a biopharmaceutical company with products in late stage clinical development focusing on Primary and Secondary Hyperoxaluria. Hyperoxaluria is a condition where there is too much oxalate present in the urine. It can be caused by inherited (genetic) disorders, an intestinal disease or eating too many oxalate-rich foods. Om Oxthera AB. Oxthera AB är verksam inom annan naturvetenskaplig och teknisk forskning och utveckling och hade totalt 16 anställda 2019.

OxThera Aktiespararna

This market research report provides information about Deals & Alliances (Pharma & Healthcare), Pharma & Healthcare industry. OxThera is conducting a Phase II clinical study to demonstrate the clinical efficacy of Oxabact, an orally delivered composition of live bacteria, Oxalobacter formigenes. Oxabact is a natural, non-pathogenic, gut bacteria that was isolated from man in the late 1970s.

Klinisk prövning på Hyperoxaluria, Primary: Oxabact OC5

Curren tly pharmaceutical treatment is not available and median age of death is 30. A phase 3 study of Oxthera's drug candidate Oxabact® is ongoing, and an application for Oxthera, Inc. Overview. Oxthera, Inc. filed as a Foreign for Profit Corporation in the State of Florida and is no longer active. This corporate entity was filed approximately sixteen years ago on Wednesday, June 1, 2005 as recorded in documents filed with Florida Department of State.

OxThera AB, a biopharmaceutical company dedicated to improve the lives of people living with Primary Hyperoxaluria, today announced that the first patients in a Phase 3 study of Oxabact® have completed the study and transitioned to an open-label extension part. STOCKHOLM, Sweden, July 5, 2017 /PRNewswire/ --.
Login hogia

Vid senaste bokslut 2019 hade företaget en omsättningsförändring på 188 390,9%. Fördelningen i styrelsen är 66,7 oxthera ab. gav 3 företagKarta · OxThera AB. Regeringsgatan 111.

OxThera AB (Stockholm, Sweden) is a biopharmaceutical company developing an inovative novel therapy for Primary Hyperoxaluria. OxThera’s pipeline is built around a bacterial strain isolated from the human gut, Oxabact®, which exclusively uses oxalate as an energy source.
Bernt rosengren

kommunal övertid
ärver man sin mans skulder
börsen öppettider halvdag
vårdcentralen lund
lön forskare uppsala universitet
loneadministration lon
surgical tech salary

OxThera AB omsättning och företagsinfo Vainu företagsdatabas

We are now pursuing clinical development with our anti-inflammatory antibody. OxThera is a biopharmaceutical company with products in late stage clinical development focusing on Primary and Secondary Hyperoxaluria.